Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

Phase 1/2 Active not recruiting 30 enrolled Intralytix, Inc. Icahn School of Medicine at Mount Sinai · collab Johns Hopkins University · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.

Timeline

Start: 2019-05-01
Primary completion: 2026-06-01
Completion: 2026-06-01

Publications

Lenneman BR, Fernbach J, Loessner MJ, Lu TK, Kilcher S. Enhancing phage therapy through synthetic biology and genome engineering. Curr Opin Biotechnol. 2021 Apr;68:151-159. doi: 10.1016/j.copbio.2020.11.003. Epub 2020 Dec 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EcoActive	Other / unclassified	1 ml	Oral

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

Summary

Timeline

Publications

Drugs

Indications